Description
Neurox Pharmacodynamics
Ethylmethylhydroxypyridine succinate is an inhibitor of free radical processes, membrane protector, which has antihypoxic, stress-protective, nootropic, anticonvulsant and anxiolytic action.
Ethylmethylhydroxypyridine succinate increases the body’s resistance to the effects of various damaging factors (shock, hypoxia and ischemia, cerebral circulation disorders, intoxication with alcohol and antipsychotic drugs (neuroleptics)).
The mechanism of action of ethylmethylhydroxypyridine succinate is due to its antioxidant, antihypoxant and membrane-protective effects. It inhibits lipid peroxidation, increases superoxide dismutase activity, increases the lipid-protein ratio, reduces membrane viscosity and increases its fluidity. Ethylmethylhydroxypyridine succinatemodulates the activity of membrane-bound enzymes (calcium independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, gamma-aminobutyric acid, acetylcholine), which increases their binding ability to ligands, helps maintain the structural and functional organization of biomembranes, transport neurotransmitters and improve synaptic transmission. Ethylmethylhydroxypyridine succinate increases the content of dopamine in the brain. Causes enhancement of compensatory activation of aerobic glycolysis and reduction of inhibition of oxidative processes in the Krebs cycle under hypoxia with an increase in adenosine triphosphate and creatine phosphate, activation of energy-synthesizing functions of mitochondria, stabilization of cell membranes.
Improves metabolism and blood supply to the brain, improves microcirculation and blood rheological properties, reduces platelet aggregation. It stabilizes membrane structures of blood cells (erythrocytes and platelets) during hemolysis.
It has a hypolipidemic effect, reduces the content of total cholesterol and low-density lipoproteins.
Anti-stressor effect is manifested in normalization of post-stress behavior, somatovegetative disorders, restoration of sleep-wake cycles, disturbed learning and memory processes, reduction of dystrophic and morphological changes in various structures of the brain.
Ethylmethylhydroxypyridine succinate has a pronounced antitoxic effect during withdrawal syndrome. It eliminates neurological and neurotoxic manifestations of acute alcohol intoxication, restores behavioral disorders, autonomic functions, and is also able to relieve cognitive disorders caused by prolonged ethanol intake and its withdrawal.
Under the influence of ethylmethylhydroxypyridine succinate the effect of tranquilizing, neuroleptic, antidepressant, sleeping pills and anticonvulsants increases, which allows reducing their doses and side effects.
Ethylmethylhydroxypyridine succinate improves functional state of ischemic myocardium. In conditions of coronary insufficiency it increases collateral blood supply of ischemic myocardium, promotes preservation of integrity of cardiomyocytes and maintenance of their functional activity. Effectively restores myocardial contractility in reversible cardiac dysfunction.
Indications
– Consequences of acute cerebral circulatory disorders, including after transient ischemic attacks, in the subcompensation phase, as preventive courses;
– Mild craniocerebral trauma, the consequences of craniocerebral injuries;
– encephalopathies of various genesis (dyscirculatory, dysmetabolic, posttraumatic, mixed);
– vegetative dystonia syndrome;
– Mild cognitive disorders of atherosclerotic genesis;
– Anxiety disorders in neurotic and neurosis-like conditions;
– coronary heart disease as part of complex therapy;
– relief of withdrawal syndrome in alcoholism with a predominance of neurotic and vegetative vascular disorders, postabstinence disorders;
– states after acute intoxication with antipsychotic drugs;
– Asthenic conditions, as well as for the prevention of the development of somatic diseases under the influence of extreme factors and stress;
– Effects of extreme (stressor) factors.
Contraindications
Acute hepatic and/or renal failure, hypersensitivity to the drug.
Because of the insufficient study of the drug – childhood, pregnancy, breast-feeding.
Lactose intolerance, lactase deficiency and glucose-galactose malabsorption syndrome.
Pregnancy and lactation:
The drug is contraindicated in pregnancy and during breast-feeding due to insufficient data on efficacy and safety of the drug during these periods.
Dosage and administration method
- Orally, 125-250 mg three times a day.
- Initial dose – 125-250 mg (1-2 tablets) 1 to 2 times a day with gradual increase until therapeutic effect is achieved; maximum daily dose – 800 mg. Duration of treatment – 2-6 weeks; for stopping alcohol withdrawal – 5-7 days.
- Treatment is discontinued gradually, reducing the dose over 2-3 days.
- The duration of therapy in patients with coronary heart disease is at least 1.5-2 months.
- Repeated courses (as recommended by the doctor), it is desirable to conduct in the spring and autumn periods.
